Selegiline use while Breastfeeding
Drugs containing Selegiline: Emsam, Eldepryl, Selgene, Carbex, Atapryl, Jumex, Zelapar
Selegiline Levels and Effects while Breastfeeding
Summary of Use during Lactation
A minimal amount of clinical use of selegiline during breastfeeding has been reported. Although no adverse reactions have been reported in the breastfed infants, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. The manufacturer of the selegiling transdermal patch recommends that breastfeeding is not recommended during treatment and for 5 days after the final dose.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. A woman with severe depression used a selegiline patch 6 mg per day during pregnancy and postpartum. She exclusively breastfed her infant. A blood sample taken from the infant on day 12 postpartum found no selegiline or its metabolite in the infants plasma. No details were provided regarding the assay or its detection limits.
Effects in Breastfed Infants
A woman took selegiline 10 mg/day, levodopa 400 mg and benserazide 100 mg daily throughout pregnancy and continued them while breastfeeding her infant for 3 days. The child was followed for 10 years and no developmental abnormalities were found.
A woman with severe depression used a selegiline patch 6 mg per day during pregnancy and postpartum. She exclusively breastfed her infant for an unstated period of time. Pediatric follow-up at 5 months of age found that the infant was developing normally.
Effects on Lactation and Breastmilk
Selegiline can decrease serum prolactin in women with migraine, and in those taking neuroleptic drugs. The clinical relevance of these findings in nursing mothers is not known. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
1. Bauer RL, Orfei J, Wichman CL. Use of transdermal selegiline in pregnancy and lactation: A case report. Psychosomatics. 2017;58:450-2. PMID: 28501290
2. Kupsch A, Oertel WH. Selegiline, pregnancy, and Parkinson's disease. Mov Disord. 1998;175-6. PMID: 9452347
3. Calabresi P, Silvestrini M, Stratta F et al. l-Deprenyl test in migraine: neuroendocrinological aspects. Cephalalgia. 1993;13:406-9. PMID: 8313454
4. Kodesh A, Weizman A, Aizenberg D et al. Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. Clin Neuropharmacol. 2003;26:193-5. PMID: 12897639
5. Perenyi A, Bagdy G, Arato M. An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism. Pharmacopsychiatria. 1983;16:143-6. PMID: 6140692
CAS Registry Number
Monoamine Oxidase Inhibitors
LactMed Record Number
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about selegiline
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- 42 Reviews – Add your own review/rating
- Drug class: dopaminergic antiparkinsonism agents
- Selegiline transdermal
- Selegiline Capsules and Tablets
- Selegiline Orally Disintegrating Tablets
- Selegiline Transdermal System
- ... +2 more